Primary Prophylaxis to Prevent Tuberculosis Infection in Prison Inmates: A Randomized, Double-Blind, Placebo-Controlled Trial.
Adult
Double-Blind Method
Humans
Incidence
Interferon-gamma Release Tests
/ methods
Isoniazid
/ administration & dosage
Latent Tuberculosis
/ drug therapy
Mycobacterium tuberculosis
/ isolation & purification
Primary Prevention
Prisoners
Prisons
/ statistics & numerical data
Tuberculin Test
/ methods
Tuberculosis
/ prevention & control
Young Adult
Journal
The American journal of tropical medicine and hygiene
ISSN: 1476-1645
Titre abrégé: Am J Trop Med Hyg
Pays: United States
ID NLM: 0370507
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
pubmed:
3
9
2020
medline:
24
11
2020
entrez:
3
9
2020
Statut:
ppublish
Résumé
In many low- and middle-income countries, tuberculosis (TB) incidence in prisons is high, exposing incarcerated populations to an elevated risk of TB infection. We conducted a randomized, double-blind, placebo-controlled trial among HIV-negative male inmates of a high TB burden prison to determine whether isoniazid given twice weekly (900 mg) for 12 months prevents TB infection. The primary outcome was QuantiFERON-TB Gold in Plus (QFT) conversion to ≥ 0.35 international units per milliliter (IU/mL) at 6 months; secondary outcomes included alternative QFT thresholds (≥ 0.7, ≥ 2.0, and ≥ 4.0 IU/mL). In total, 467 participants were randomly assigned to intervention (
Identifiants
pubmed: 32876010
doi: 10.4269/ajtmh.20-0110
pmc: PMC7543866
doi:
Substances chimiques
Isoniazid
V83O1VOZ8L
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1466-1472Références
Emerg Infect Dis. 2017 Mar;23(3):496-499
pubmed: 28221118
PLoS One. 2013;8(1):e54748
pubmed: 23382955
PLoS Med. 2010 Dec 21;7(12):e1000381
pubmed: 21203587
Ann Intern Med. 2017 Nov 21;167(10):689-697
pubmed: 29114781
Swiss Med Wkly. 2011 Aug 15;141:w13240
pubmed: 21842452
Am Rev Respir Dis. 1979 May;119(5):827-30
pubmed: 453704
Chest. 1972 Jul;62(1):71-7
pubmed: 4339326
PLoS Med. 2019 Jan 24;16(1):e1002737
pubmed: 30677013
Bibl Tuberc. 1970;26:28-106
pubmed: 4903501
Lancet Respir Med. 2017 Apr;5(4):282-290
pubmed: 28215501
Clin Infect Dis. 2015 Feb 15;60(4):639-45
pubmed: 25365974
Am J Respir Crit Care Med. 2006 Oct 15;174(8):935-52
pubmed: 17021358
Am J Respir Crit Care Med. 2017 Sep 1;196(5):638-648
pubmed: 28737960
Bull World Health Organ. 1965;33(3):419-33
pubmed: 5321762
Lancet. 2016 Sep 10;388(10049):1089-1102
pubmed: 27427453
Clin Pharmacokinet. 1979 Nov-Dec;4(6):401-22
pubmed: 391461
West J Med. 1993 Nov;159(5):560-4
pubmed: 8279152
Epidemiol Infect. 2017 Sep;145(12):2491-2499
pubmed: 28756786
N Engl J Med. 2012 Oct 4;367(14):1355-60
pubmed: 23034025
Int J Tuberc Lung Dis. 2016 Aug;20(8):1072-7
pubmed: 27393542
Am J Respir Crit Care Med. 2015 Mar 1;191(5):584-91
pubmed: 25562578
N Engl J Med. 2014 Jan 23;370(4):301-10
pubmed: 24450889
Am J Trop Med Hyg. 2015 Oct;93(4):739-46
pubmed: 26195459
Am J Respir Crit Care Med. 2013 Oct 15;188(8):1005-10
pubmed: 23978270
N Engl J Med. 2018 Jul 12;379(2):138-149
pubmed: 29996082
Am J Respir Crit Care Med. 2014 Jan 1;189(1):77-87
pubmed: 24299555
J Correct Health Care. 2012 Apr;18(2):131-42
pubmed: 22419641
Eur Respir J. 2011 Oct;38(4):752-4
pubmed: 21965498
N Engl J Med. 2018 Aug 2;379(5):440-453
pubmed: 30067931
Am J Respir Crit Care Med. 2020 Apr 15;201(8):984-991
pubmed: 31825645
P T. 2013 Apr;38(4):225-7
pubmed: 23785228
Lancet. 2016 Sep 17;388(10050):1215-27
pubmed: 27427448
BMC Infect Dis. 2015 Jan 22;15:24
pubmed: 25608746
Int J Tuberc Lung Dis. 2010 Nov;14(11):1374-81
pubmed: 20937175
Thorax. 2018 Apr 5;:
pubmed: 29622693
BMC Infect Dis. 2016 Oct 3;16(1):533
pubmed: 27716170
Int J Tuberc Lung Dis. 2013 Jul;17(7):909-16
pubmed: 23743310